A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for
metastatic pancreatic adenocarcinoma (a type of pancreatic cancer). Subjects are randomized
between a control group (standard treatment) and an intervention group (pharmacologic
ascorbate in addition to the standard treatment).
Phase:
Phase 2
Details
Lead Sponsor:
Joseph J. Cullen University of Iowa
Collaborators:
Holden Comprehensive Cancer Center McGuff Pharmaceuticals, Inc. National Cancer Institute (NCI) National Institutes of Health (NIH)